Literature DB >> 18997221

Medicare's national coverage decisions for technologies, 1999-2007.

Peter J Neumann1, Maki S Kamae, Jennifer A Palmer.   

Abstract

An analysis of Medicare national coverage decisions (NCDs) from 1999 through 2007 reveals that the Centers for Medicare and Medicaid Services (CMS) considers the available evidence as no better than fair for most of the technologies considered. Still, the CMS issues favorable decisions in 60 percent of the cases it takes on, although almost always with conditions placed on coverage. Since enactment of the 2003 Medicare Modernization Act, which legislated maximum review times for NCDs, the CMS has eliminated "long duration" decisions (more than one year) and has issued several "coverage with evidence development" decisions, which promise flexibility but also carry implementation challenges.

Mesh:

Year:  2008        PMID: 18997221     DOI: 10.1377/hlthaff.27.6.1620

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  9 in total

1.  Medicare's policy on carotid stents limited use to hospitals meeting quality guidelines yet did not hurt disadvantaged.

Authors:  Peter W Groeneveld; Andrew J Epstein; Feifei Yang; Lin Yang; Daniel Polsky
Journal:  Health Aff (Millwood)       Date:  2011-02       Impact factor: 6.301

Review 2.  Evaluation of technologies approved for supplemental payments in the United States.

Authors:  Timothy J Judson; Sanket S Dhruva; Rita F Redberg
Journal:  BMJ       Date:  2019-06-17

Review 3.  Performance-Based Risk-Sharing Arrangements: An Updated International Review.

Authors:  Josh J Carlson; Shuxian Chen; Louis P Garrison
Journal:  Pharmacoeconomics       Date:  2017-10       Impact factor: 4.981

4.  Paying for Frequent Dialysis.

Authors:  Adam S Wilk; Richard A Hirth; Joseph M Messana
Journal:  Am J Kidney Dis       Date:  2019-03-25       Impact factor: 8.860

5.  What is evidence?

Authors:  Sharon-Lise T Normand; Barbara J McNeil
Journal:  Stat Med       Date:  2010-08-30       Impact factor: 2.373

6.  Impact of alternative medical device approval processes on costs and health.

Authors:  Benjamin P George; Vinayak Venkataraman; E Ray Dorsey; S Claiborne Johnston
Journal:  Clin Transl Sci       Date:  2014-09-03       Impact factor: 4.689

7.  Persistent Variation in Medicare Payment Authorization for Home Hemodialysis Treatments.

Authors:  Adam S Wilk; Richard A Hirth; Wei Zhang; John R C Wheeler; Marc N Turenne; Tammie A Nahra; Kathryn K Sleeman; Joseph M Messana
Journal:  Health Serv Res       Date:  2017-01-19       Impact factor: 3.734

8.  Selecting the Acceptance Criteria of Medicines in the Reimbursement List of Public Health Insurance of Iran, Using the "Borda" Method: a Pilot Study.

Authors:  Amir Viyanchi; Hamid Reza Rasekh; Ali Rajabzadeh Ghatari; Hamid Reza SafiKhani
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

9.  Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016: A cross-sectional study.

Authors:  Aliya C Roginiel; Sanket S Dhruva; Joseph S Ross
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.